BioSpace News Archive

Virtual Incision Corporation today announced the U.S. Food and Drug Administration (FDA) has approved an Investigational Device Exemption (IDE) supplement to complete the final stage of its clinical study analyzing the MIRA ® Platform in bowel resection procedures.

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer, and Sri Vaddeboina, PhD, Senior Vice President, Chemistry, Manufacturing and Controls, are scheduled to participate virtually in an analyst-led fireside chat at Chardan’s 6th Annual Genetic Medicines & Cell Therapy Manufacturing Summit.

Surmodics, Inc. today announced that it will host a live webcast of its second quarter fiscal 2022 conference call on Wednesday, April 27, at 7:30 a.m. CT (8:30 a.m. ET).

Simulations Plus, Inc. today announced that management will be participating in the Berenberg Discover AI Seminar at The Newbury Boston in Boston, Massachusetts, on April 26, 2022.

The PPD clinical research business of Thermo Fisher Scientific Inc. and Matrix Clinical Trials, a Matrix Medical Network offering, are collaborating to bring clinical trials to patients with an innovative decentralized clinical trial (DCT) solution.

Rise in the number of older population across the globe is projected to boost the demand for urgent care centers globally.

Albany NY, United States: The increasing prevalence of cardiovascular disorders and technological advancement in the field of medical science are likely to aid in the expansion of the global interventional radiology market.

Pixium Vision SA announces a cash position of €10.4 million at 31 March 2022 and reports on its key developments.

According to the report, the global reprocessed medical devices market was valued at US$ 2.05 Bn in 2020 and is projected to expand at a CAGR of 14.9% from 2021 to 2028.

Soligenix, Inc. announced today that it has received approximately $1.4 million, net of transaction costs, in non-dilutive funding via multiple government tax programs.